A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective

References

• Hattenhauer MG Johnson DH, Ing, HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105:2099–104
   Google Scholar
• Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull WHO 2004;82: 844–51
   Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90: 262–7
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wolfs RC, O’Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–8
   Google Scholar
• Nordmann J, Touboul C, Auzanneau N, et al. Vision related quality of life of French patients is affected by topical glaucoma treatment side effects. Poster presented at: ISPOR 5th Annual European Congress; November 3–5, 2002; Rotterdam, the Netherlands
   Google Scholar
• AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al., for the Ocular Hypertension Treatment Study. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   Google Scholar
• Heijl A, Leske MC, Bengtsson B et al., for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268–79
   Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al., for the GanfortR Investigators Group II. Bimatoprost/Timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008;17: in press
   Google Scholar
• Hughes BA, Bacharach J, Craven R, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005;14: 392–9
   Google Scholar
• Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242–50
   Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1–7
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI, for the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus individual components. Ophthalmology 2006;113: 70–6
   Google Scholar
• Council of Europe. European Pharmacopoeia, 5th edn. Strasbourg, France: European Directorate for the Quality of Medicines & Healthcare, 2004:602–3
   Google Scholar
• IMS Medical prices. August 2007
   Google Scholar
• Krieglstein G, Jonsson B, Kobelt G. Primary open-angle glaucoma: differences in international treatment patterns and costs. Oxford, UK: Isis Medical Media, 1999
   Google Scholar
• Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LumiganR) versus combined timolol and dorzolamide (CosoptR) in patients with glaucoma or ocular hypertension. Ophthalmology 2003;110: 2362–8
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550–5
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al. for the Bimatoprost/ Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55–63
   Google Scholar
• Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135: 688–703
   Google Scholar
• Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007;2:1025–32
   Google Scholar
• Department of Health. National Schedule of Reference Costs 2007; http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_062884. Accessed July 2007
   Google Scholar
• Norrlandstingens regionforbund. Prislista 2007. Available at http://www.norrlandstingen.se. Accessed August 28th, 2007
   Google Scholar
• Den norske lageforening. Normaltariff for privat specialistpraksis. http://www.legeforeningen.no/assets/Normaltariffen_2007.pdf. Accessed August 21, 2007
   Google Scholar
• Nomenclatore tariffario. Ministero della Sanita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del SSN e relative tariffe. DM 22 Luglio, 1996
   Google Scholar
• Soikos. Base de datos de costes sanitarios. Version 2.1. Available through http://www.soikos.org. Accessed July 2007
   Google Scholar